SynthesisEmerging microbes & infections2025
Association between baseline HIV-1 DNA levels and clinical outcomes in people living with HIV: a meta-analysis of cohort studies.
Synthesis in Emerging microbes & infections, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Nucleic acid testing-optimized HIV diagnostic algorithms: a multimethod comparative effectiveness analysis in clinical practice.British journal of biomedical science · 2026Article
- The performance of low HIV viral load values for the diagnosis of acute HIV infection in the Beijing PRIMO cohort.BMC infectious diseases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To assess the prognostic value of baseline HIV-1 DNA levels, a meta-analysis was conducted according to the PROSPERO protocol (CRD42024619050) based on data from studies published until March 4, 2025. Relevant studies were retrieved from the Web of Science, PubMed, Cochrane Library, Embase, and Scopus databases. Effect sizes (correlation coefficients, odds ratios [ORs], hazard ratios [HRs], and adjusted hazard ratios [aHRs]) were calculated using R software, with subgroup analyses and assessment of publication bias and sensitivity. Seventeen studies involving 4789 participants were included. The combined correlation coefficient between pre - and on-ART HIV-1 DNA levels was 0.71 (95% confidence Interval (CI): 0.63-0.78). Baseline DNA levels were significantly associated with viral rebound after viral suppression (combined OR = 1.74, 95% CI: 1.25-2.41; HR = 2.01, 95% CI: 1.58-2.56; aHR = 2.26, 95% CI: 1.75-2.92). For clinical progression, the combined HR and aHR for continuous baseline DNA were 3.66 (95% CI: 2.87-4.66) and 2.44 (95% CI: 1.87-3.20), respectively, with high baseline DNA levels associated with an increased risk of clinical progression (HR = 2.58, 95% CI: 1.96-3.39; aHR = 1.90, 95% CI: 1.41-2.55). For mortality, the HR and aHR were 3.22 (95% CI: 1.96-5.29) and 2.15 (95% CI: 1.21-3.84) respectively, with high baseline DNA levels associated with an increased risk of death (HR = 3.54, 95% CI: 1.39-9.00; aHR = 2.86, 95% CI: 1.01-8.08). Higher pre-ART HIV-1 DNA levels are associated with increased risks of viral rebound, clinical progression, and mortality. These results suggest that baseline HIV-1 DNA represents a potentially valuable supplementary biomarker for monitoring disease progression and treatment response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.